Antimicrobial Resistance: Perspectives from the Public Health Agency of Canada

Marc-André Gaudreau
Manager, Strategic Issues, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada

• An overview of the Agency’s role with respect to antimicrobial resistance will be provided.
• Monitoring AMR from farm to fork – results from the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS)

Rita Finley
Senior Epidemiologist, Surveillnce Division of the Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada.

• Following antimicrobial resistant Salmonella isolated from farm, abattoir, retail and human clinical cases. Ms Finley will also share updates on the human antimicrobial use surveillance that is carried out by CIPARS.


• Antimicrobial Resistant Neisseria gonorrhoeae in Canada: a National Perspective

Irene Martin
Head, Streptococcus and STI Unit, National Microbiology Laboratory, Public Health Agency of Canada

• In Canada, reported rates of gonorrhea infection have been increasing yearly since 1997. Neisseria gonorrhoeae isolates with decreasing susceptibilities to the cephalosporins used for treatment are on the rise, threatening the available drug treatment options for gonorrhea infections. The Public Health Agency of Canada’s National Microbiology Laboratory monitors the antimicrobial susceptibilities of N. gonorrhoeae to ensure the effectiveness of recommended treatments and timely detection of emerging resistance mechanisms.


• Public Health Updates on the Management of multidrug resistant gonorrhea (MDR-GC)

Dr. Thomas Wong, MD, MPH, CCFP, FRCPC
Director of Professional Guidelines and Public Health Practice Division, Centre for Communicable Diseases & Infection Control, Public Health Agency of Canada

• Dr. Wong will share treatment recommendations from the Canadian Guidelines on Sexually Transmitted Infections that have been updated in response to increasing gonococcal antimicrobial resistance.

Log in early as space limited.

Abstract:
Comparative effectiveness research evaluates benefits and harms of alternative treatments. A causal connection between treatment choice and outcomes can be demonstrated by comparing patients randomly assigned to one of the treatments. However, not all causal questions can be answered through even well-designed experiments. For example, questions of attribution (What proportion of patients treated with A would have survived, had they been treated with B?) and questions of susceptibility (What proportion of patients treated with B would have died, had they been treated with A?) cannot be answered with data alone. Such questions require counterfactual analysis of the observed data, since only the outcome of one treatment alternative can be observed for a given patient. In this talk, I discuss the causalilty perspective in comparing effectiveness of alternative interventions in coronary revascularization.

Speaker: Dr. Boris Sobolev
Professor and Canada Research Chair
School of Population and Public Health
The University of British Columbia

Please note: this is a new date, updated from November 23rd.

All faculty are invited to attend

Ed Chessor, MBA, PEng, Adjunct Professor, UBC School of Population & Public Health